Changes in oscillometry in interstitial lung disease

  • Research type

    Research Study

  • Full title

    Changes in impulse oscillometry measurements and outcomes in idiopathic pulmonary fibrosis

  • IRAS ID

    282567

  • Contact name

    William Man

  • Contact email

    W.Man@rbht.nhs.uk

  • Sponsor organisation

    Royal Brompton & Harefield NHS Foundation Trust

  • Duration of Study in the UK

    6 years, 6 months, 31 days

  • Research summary

    Idiopathic pulmonary fibrosis (IPF) is a condition where scar tissue (called fibrosis) builds up in the lungs. It usually gets worse over time. Fibrosis causes the lungs to become stiff, and reduces the amount of oxygen that the lungs can take up. People with IPF complain of worsening breathlessness, which limits their day to day activities.

    Lung function tests are breathing tests that measure how well your lungs are working, and are used by doctors to decide whether to start or stop medicines in people with IPF. However, people with IPF tell us that lung function tests require a lot of effort, can make them cough and feel very short of breath. About 1 in 5 people with IPF are unable to perform lung function results accurately. This might unfairly lead to some people with IPF not receiving the right medications or for their medications to be stopped too soon.

    Impulse oscillometry (iOS) uses sound waves to measure the stiffness of the lung, and has been used successfully in children who are unable to perform normal lung function tests.

    The overall aim of the research is to see whether changes in iOS measures can give useful information about the lungs in patients with IPF; for example, by judging the overall impact of the disease on the lungs, or predicting future deterioration.

    We will look at how iOS changes over time in patients with IPF, and to see whether these measurements can tell us about whether IPF is getting worse or predict important health events, such as hospital admission. We will compare change in iOS with changes in other tests used to monitor IPF and with patient reported ratings of change in their condition. This will help decide the amount of iOS change that is noticed and considered meaningful by people with IPF.

  • REC name

    London - London Bridge Research Ethics Committee

  • REC reference

    20/LO/0969

  • Date of REC Opinion

    11 Aug 2020

  • REC opinion

    Favourable Opinion